A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）

Inclusion Criteria: 1. age ≥18 years old, gender not limited; 2. Laboratory (RT-PCR) confirmed COVID-19; 3. the time from the first positive nucleic acid test to randomization does not exceed more than 4 days; 4. informed consent has been signed. Exclusion Criteria: 1. known or suspected allergies to the components of azivudine tablets; 2. according to the latest version of the National Health and Medical Commission Diagnostic criteria of COVID-19, patients with severe novel coronavirus pneumonia was confirmed; 3. severe liver disease (TBIL\>=2 times normal upper limit; ALTAST\>=5 times normal upper limit); 4. subjects with severe renal insufficiency (glomerular filtration rate ≤60 mL/min/1.73 m2) or undergoing continuous renal replacement therapy, hemodialysis or peritoneal dialysis; 5. subjects with complication of malabsorption syndrome or any other condition affecting gastrointestinal absorption, requiring intravenous nutrition or not being able to take drugs orally; 6. subjectsis currently receiving anti-hiv treatment; 7. women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial; 8. participating in other clinical trials or using experimental drugs, except traditional Chinese medicine; 9. Other conditions that not appropriate to be enrolled into this study based on investigator's advise.